Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference12 articles.
1. Fu H, Zheng Z, Zhang Z et al (2023) Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol. https://doi.org/10.1007/s10067-023-06570-3
2. Wodkowski M, Hudson M, Proudman S et al (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33:S131–S135
3. Meridor K, Sagy I, Molad Y (2022) Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. Mod Rheumatol 32:1086–1093. https://doi.org/10.1093/mr/roab118
4. Gunnarsson R, El-Hage F, Aaløkken TM et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55:103–108. https://doi.org/10.1093/rheumatology/kev300
5. Sabbagh S, Pinal-Fernandez I, Kishi T et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78:988–995. https://doi.org/10.1136/annrheumdis-2018-215004